CompaniesThallion Pharmaceuticals

Thallion Pharmaceuticals

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (5)
View all

Total Trials

5

As Lead Sponsor

5

As Collaborator

0

Total Enrollment

170

By Phase

PHASE2: 4PHASE1: 1

By Status

COMPLETED: 3TERMINATED: 2
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
Today
NCT00338026
NCT00730262
NCT00735332
NCT01252199
Hover over trial bars to see details

Recent Trials

NCT01252199Lead Sponsor
Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2
PHASE2Completed
45 participants
Started: Nov 30, 2010 · Completed: Feb 28, 2013
NCT00730262Lead Sponsor
Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme
PHASE2Terminated
40 participants
Started: Aug 31, 2008 · Completed: Jun 30, 2010
NCT00735332Lead Sponsor
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma
PHASE2Terminated
49 participants
Started: Aug 31, 2008 · Completed: Oct 31, 2010
NCT00422786Lead Sponsor
Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma
PHASE2Completed
10 participants
Started: Mar 31, 2007 · Completed: Mar 31, 2008
NCT00338026Lead Sponsor
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
PHASE1Completed
26 participants
Started: Feb 28, 2006 · Completed: Aug 31, 2007